Cargando…

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages

Antibody-dependent cellular phagocytosis (ADCP) by macrophages, an important effector function of tumor targeting antibodies, is hampered by ‘Don´t Eat Me!’ signals such as CD47 expressed by cancer cells. Yet, human leukocyte antigen (HLA) class I expression may also impair ADCP by engaging leukocyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeller, Tobias, Lutz, Sebastian, Münnich, Ira A., Windisch, Roland, Hilger, Patricia, Herold, Tobias, Tahiri, Natyra, Banck, Jan C., Weigert, Oliver, Moosmann, Andreas, von Bergwelt-Baildon, Michael, Flamann, Cindy, Bruns, Heiko, Wichmann, Christian, Baumann, Niklas, Valerius, Thomas, Schewe, Denis M., Peipp, Matthias, Rösner, Thies, Humpe, Andreas, Kellner, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647079/ https://www.ncbi.nlm.nih.gov/pubmed/36389667 http://dx.doi.org/10.3389/fimmu.2022.929339

Ejemplares similares

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
por: Zeller, Tobias, et al.
Publicado: (2023)

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
por: Roßkopf, Sophia, et al.
Publicado: (2020)

Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions
por: Baumann, Niklas, et al.
Publicado: (2021)

Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo
por: Winterberg, Dorothee, et al.
Publicado: (2021)

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody
por: Gehlert, Carina Lynn, et al.
Publicado: (2022)

Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96
por: Mohseni Nodehi, Sahar, et al.
Publicado: (2012)

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
por: Kellner, Christian, et al.
Publicado: (2018)

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
por: Baumann, Niklas, et al.
Publicado: (2022)

Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy
por: Klausz, Katja, et al.
Publicado: (2020)

A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries
por: Klausz, Katja, et al.
Publicado: (2017)

Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia
por: Windisch, Roland, et al.
Publicado: (2019)

Strategies for purging CD96(+) stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukemia
por: Staudinger, Matthias, et al.
Publicado: (2013)

The impact of HLA-G, LILRB1 and LILRB2 gene polymorphisms on susceptibility to and severity of endometriosis
por: Bylińska, Aleksandra, et al.
Publicado: (2017)

The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2012)

Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies
por: Macarrón Palacios, Arturo, et al.
Publicado: (2020)

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity
por: Peipp, Matthias, et al.
Publicado: (2015)

Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection
por: Khatamzas, Elham, et al.
Publicado: (2022)

Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
por: Evers, Mitchell, et al.
Publicado: (2020)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex
por: Wang, Qihui, et al.
Publicado: (2019)

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
por: Lenk, Lennart, et al.
Publicado: (2022)

LILRB4, an immune checkpoint on myeloid cells
por: Yang, Ting, et al.
Publicado: (2022)

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
por: Vogiatzi, Fotini, et al.
Publicado: (2022)

Impact of the NK Cell Receptor LIR-1 (ILT-2/CD85j/LILRB1) on Cytotoxicity against Multiple Myeloma
por: Heidenreich, Silke, et al.
Publicado: (2012)

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report
por: Rejeski, Kai, et al.
Publicado: (2021)

Molecular regulatory mechanism of LILRB4 in the immune response
por: LIU, Haiyin, et al.
Publicado: (2023)

Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype
por: Kellner, Christian, et al.
Publicado: (2013)

Differential expression of CD8 defines phenotypically distinct cytotoxic T cells in cancer and multiple sclerosis
por: Burkard, Tobias, et al.
Publicado: (2022)

The decay of $^{104}$Cd
por: Münnich, F, et al.
Publicado: (1970)

The decay of $^{102}$Cd
por: Hnatowich, D J, et al.
Publicado: (1970)

The decay of $^{102}Cd$
por: Hnatowich, D J, et al.
Publicado: (1970)

The decay of $^{104}Cd$
por: Münnich, F, et al.
Publicado: (1970)

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
por: Karschnia, Philipp, et al.
Publicado: (2021)

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
por: Blumenberg, Viktoria, et al.
Publicado: (2023)

Tribody [(HER2)(2)xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
por: Oberg, Hans H., et al.
Publicado: (2018)

HLA-G, LILRB1 and LILRB2 Variants in Zika Virus Transmission from Mother to Child in a Population from South and Southeast of Brazil
por: de Moraes, Amarilis Giaretta, et al.
Publicado: (2022)

Conditional Immortalization of Human B Cells by CD40 Ligation
por: Wiesner, Martina, et al.
Publicado: (2008)

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
por: Rejeski, Kai, et al.
Publicado: (2022)

Regulation of CD4(+) and CD8(+) T Cell Biology by Short-Chain Fatty Acids and Its Relevance for Autoimmune Pathology
por: Schiweck, Carmen, et al.
Publicado: (2022)

Enhanced CXCR4 Expression of Human CD8(Low) T Lymphocytes Is Driven by S1P(4)
por: Burkard, Tobias, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d63rbqb4pq89imn2a6oq50m61e